Responses
Clinical/translational cancer immunotherapy
Original research
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.